Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 1775 W Oak Commons Court, Ne MARIETTA GA 30062 |
Tel: | N/A |
Website: | https://mimedx.com |
IR: | See website |
Key People | ||
Joseph H. Capper Chief Executive Officer, Director | Douglas C. Rice Chief Financial Officer, Chief Accounting Officer | Ricci S. Whitlow Executive Vice President, Chief Operating Officer | William Frank Hulse Chief Administrative Officer, General Counsel |
Business Overview |
MiMedx Group, Inc. is a placental biologics company. The Company is engaged in developing and distributing placental tissue allografts with patent-protected, processes for multiple sectors of healthcare. Its product portfolio categories include Wound Care Products, and Surgical and Other Products. Its Wound Care Products include EPIFIX, EPICORD and EPIEFFECT, which are all marketed for external use, such as in advanced wound care applications. Its Surgical and Other product offering includes AMNIOFIX, AMNIOCORD and AMNIOEFFECT, which are positioned for use in a variety of applications and surgical settings, including lower extremity repair, plastic surgery, vascular surgery and multiple orthopedic repairs and reconstructions. The Company's platform technologies include tissue allografts derived from the human placental membrane, tissue allografts derived from the human umbilical cord, and a particulate extracellular matrix derived from the human placental disc. |
Financial Overview |
For the three months ended 31 March 2024, MiMedx Group Inc revenues increased 18% to $84.7M. Net income applicable to common stockholders excluding extraordinary items totaled $9.1M vs. loss of $3.6M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Net Income reflects Investigation, restatement and related decrease of 92% to $311K (expense). |